Johnson & Johnson

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell JNJ and other ETFs, options, and stocks.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

CEO

Joaquin Duato

CEOJoaquin Duato

Employees

131,900

Employees131,900

Headquarters

New Brunswick, New Jersey

HeadquartersNew Brunswick, New Jersey

Founded

1887

Founded1887

Employees

131,900

Employees131,900

JNJ Key Statistics

Market cap

356.69B

Market cap356.69B

Price-Earnings ratio

24.30

Price-Earnings ratio24.30

Dividend yield

3.34%

Dividend yield3.34%

Average volume

9.37M

Average volume9.37M

High today

$149.00

High today$149.00

Low today

$147.05

Low today$147.05

Open price

$147.39

Open price$147.39

Volume

11.11M

Volume11.11M

52 Week high

$168.85

52 Week high$168.85

52 Week low

$140.68

52 Week low$140.68

JNJ News

Benzinga 29m

Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025. Analysts expect the New Brunsw...

Benzinga 10h

Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?

Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company re...

Benzinga 12h

Johnson & Johnson Q4 Preview: Can Earnings Bring Health Care 'Back To Life'?

The healthcare sector will be on watch Wednesday with a highly anticipated earnings report from Johnson & Johnson JNJ before market open. Earnings Estimates: A...

Analyst ratings

55%

of 22 ratings

Buy

45.5%

Hold

54.5%

Sell

More JNJ News

Seeking Alpha 13h

Johnson & Johnson Q4 2024 Earnings Preview: Double-digit decline in profit expected

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q4 earnings results on Wednesday, January 22nd, before market open. Analysts expect a profit per share of...

Benzinga 14h

FDA Approves Johnson & Johnson's Treatment As First Monotherapy For Treatment-Resistant Depression

On Tuesday, the FDA approved Johnson & Johnson’s JNJ supplemental New Drug Application for Spravato (esketamine) CIII nasal spray. The approval makes the treat...

Seeking Alpha 17h

J&J wins label expansion for depression therapy Spravato

Johnson & Johnson (NYSE:JNJ) announced Tuesday that the U.S. FDA approved a supplemental New Drug Application for its depression therapy Spravato (esketamine),...

CNBC 18h

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

The Food and Drug Administration on Tuesday approved Johnson & Johnson 's nasal spray to be used alone in adults with a major depressive disorder that is diffic...

TipRanks 20h

Johnson & Johnson price target lowered to $159 from $160 at Barclays

Barclays lowered the firm’s price target on Johnson & Johnson to $159 from $160 and keeps an Equal Weight rating on the shares. The firm says its 2025 medical t...

TipRanks 20h

Johnson & Johnson Q4 Pre-Earnings: Here’s What to Expect

Healthcare giant Johnson & Johnson (JNJ) is gearing up to release its fourth-quarter 2024 financials on January 22. Wall Street analysts expect the company to r...

TipRanks 3d

Johnson & Johnson’s New Acquisition Could Result in Tremendous Rewards

Staying ahead of the competition is critical in every sector, particularly in the dynamic healthcare space, where a single breakthrough treatment can result in...